

Press Release

Apogenix to Present at Three Upcoming International Conferences

Heidelberg, Germany, Oct. 13, 2015 – Apogenix, a next generation immuno-oncology company, announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at the BIO Investor Forum, the Sofinnova Japan Biopharma Partnering Conference, and the German Equity Forum.

BIO Investor Forum

Venue: Parc 55, San Francisco, CA, USA

Presentation: October 20, 2015, 8:30 a.m. PDT, Room Davidson

Sofinnova Japan Biopharma Partnering Conference

Venue: Conrad Hotel, Tokyo, Japan

Presentation: October 27, 2015, 8:45 a.m. JST, Room Nagisa

German Equity Forum

Venue: Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt am Main, Germany

Presentation: November 25, 2015, 10:30 a.m. CEST, Room Oslo

About Apogenix

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 50 million euros from its investors and received public grants and upfront payments from licensing agreements totaling more than 20 million euros. The company is based in Heidelberg, Germany.

Contact

Thomas Hoeger, Ph.D., CEO

Apogenix GmbH

Phone: +49 (6221) 58 60 80

E-Mail: contact@apogenix.com

Web: www.apogenix.com

Media Contacts

USA:

Matt Middleman, M.D.

Russo Partners, LLC

Phone: +1 (212) 845 4272

matt.middleman@russopartnersllc.com

Europe:

Raimund Gabriel

MC Services AG

Phone: +49 (89) 210 228 30

raimund.gabriel@mc-services.eu